Is the Market Going to Go Lower?
The last month has been extremely difficult for the stock…
Sell
27
PCRX Quote, Financials, Valuation and Earnings
Last price:
$23.40
Seasonality move
:
5.17%
Day range:
$23.07 - $23.52
52-week range:
$11.16 - $31.67
Dividend yield:
0%
P/E ratio:
11.70x
P/S ratio:
1.62x
P/B ratio:
1.39x
Volume:
613.2K
Avg. volume:
795.8K
1-year change:
-20.74%
Market cap:
$1.1B
Revenue:
$701M
EPS (TTM):
-$2.19
Analysts' Opinion
-
Consensus RatingPacira BioSciences has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 4 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $30.86, Pacira BioSciences has an estimated upside of 32.38% from its current price of $23.31.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $21.00 representing 100% downside risk from its current price of $23.31.
Fair Value
-
According to the consensus of 5 analysts, Pacira BioSciences has 32.38% upside to fair value with a price target of $30.86 per share.
PCRX vs. S&P 500
-
Over the past 5 trading days, Pacira BioSciences has underperformed the S&P 500 by -0.44% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Pacira BioSciences does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Pacira BioSciences has grown year-over-year revenues for 5 quarters straight. In the most recent quarter Pacira BioSciences reported revenues of $187.3M.
Earnings Growth
-
Pacira BioSciences earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Pacira BioSciences reported earnings per share of $0.34.
Enterprise value:
1.2B
EV / Invested capital:
0.86x
Price / LTM sales:
1.62x
EV / EBIT:
8.08x
EV / Revenue:
1.68x
PEG ratio (5yr expected):
--
EV / Free cash flow:
6.60x
Price / Operating cash flow:
6.36x
Enterprise value / EBITDA:
40.50x
Gross Profit (TTM):
$530.5M
Return On Assets:
-6.32%
Net Income Margin (TTM):
-14.2%
Return On Equity:
-11.94%
Return On Invested Capital:
-7.14%
Operating Margin:
15.77%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $666.8M | $675M | $701M | $181.2M | $187.3M | |
| Gross Profit | $467.5M | $490.3M | $530.5M | $133.6M | $147.4M | |
| Operating Income | $70.9M | $87.3M | $97.6M | $34M | $29.5M | |
| EBITDA | $140.4M | $154.6M | $29.1M | $54.9M | $50.6M | |
| Diluted EPS | $0.31 | $0.83 | -$2.19 | $0.52 | $0.34 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $651.6M | $866M | $498.3M | $510M | $745.1M | |
| Total Assets | $1.3B | $2.1B | $1.7B | $1.6B | $1.6B | |
| Current Liabilities | $253.3M | $521.1M | $147.8M | $97.4M | $309.9M | |
| Total Liabilities | $654.8M | $1.3B | $906.2M | $704.3M | $775.2M | |
| Total Equity | $619.7M | $730.4M | $775M | $870.1M | $778.3M | |
| Total Debt | $462.7M | $1B | $689.5M | $522.4M | $585.3M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $145.3M | $154.6M | $189.4M | $47.6M | $33.1M | |
| Cash From Investing | -$225.2M | $77.5M | -$83.3M | $8.4M | -$368K | |
| Cash From Financing | -$401.5M | -$183M | $17.4M | -$1.8M | -$2M | |
| Free Cash Flow | $115.2M | $139.5M | $178.8M | $45.8M | $31M | |
PCRX
Sector
Market Cap
$1.1B
$37.4M
Price % of 52-Week High
73.6%
45.61%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.75%
1-Year Price Total Return
-20.74%
-38.36%
Beta (5-Year)
0.860
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$23.10
200-day SMA
Buy
Level
$20.35
Bollinger Bands (100)
Buy
Level
17.2 - 24.3
Chaikin Money Flow
Buy
Level
15.6M
20-day SMA
Sell
Level
$24.34
Relative Strength Index (RSI14)
Sell
Level
45.57
ADX Line
Sell
Level
27.86
Williams %R
Neutral
Level
-69.4758
50-day SMA
Sell
Level
$23.62
MACD (12, 26)
Sell
Level
-0.44
25-day Aroon Oscillator
Sell
Level
-80
On Balance Volume
Neutral
Level
58.6M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.1702)
Sell
CA Score
(Annual)
Level (-0.3086)
Buy
Beneish M-Score
(Annual)
Level (-3.4851)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-0.5157)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Stock Forecast FAQ
In the current month, PCRX has received 1 Buy ratings 4 Hold ratings, and 0 Sell ratings. The PCRX average analyst price target in the past 3 months is $30.86.
-
Where Will Pacira BioSciences Stock Be In 1 Year?
According to analysts, the consensus estimate is that Pacira BioSciences share price will rise to $30.86 per share over the next 12 months.
-
What Do Analysts Say About Pacira BioSciences?
Analysts are divided on their view about Pacira BioSciences share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Pacira BioSciences is a Sell and believe this share price will drop from its current level to $21.00.
-
What Is Pacira BioSciences's Price Target?
The price target for Pacira BioSciences over the next 1-year time period is forecast to be $30.86 according to 5 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 4 analysts rate the stock a Hold.
-
Is PCRX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Pacira BioSciences is a Hold. 4 of 5 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of PCRX?
You can purchase shares of Pacira BioSciences via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Pacira BioSciences shares.
-
What Is The Pacira BioSciences Share Price Today?
Pacira BioSciences was last trading at $23.40 per share. This represents the most recent stock quote for Pacira BioSciences. Yesterday, Pacira BioSciences closed at $23.31 per share.
-
How To Buy Pacira BioSciences Stock Online?
In order to purchase Pacira BioSciences stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
2 Dividend Stocks to Buy in a Recession
While many economists and investors initially expected 2025 to be…
Is Ford Stock Undervalued Amid the EV Transition?
There is a lot going on in the electric vehicle…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
54
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 41x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Buy
63
EXOD alert for Mar 18
Exodus Movement [EXOD] is down 3.96% over the past day.
Sell
45
MNPR alert for Mar 18
Monopar Therapeutics [MNPR] is up 0.93% over the past day.
Sell
47
CELH alert for Mar 18
Celsius Holdings [CELH] is up 1.44% over the past day.
